



International Cohort Consortium
of Infectious Diseases

RESPOND Newsletter

November 2025

Dear RESPOND Study Investigators and Collaborators,

The RESPOND Coordinating Centre extends the warmest greetings. We are happy to express our sincere gratitude for your continued outstanding work and invaluable contributions to the RESPOND study. Your efforts are immensely cherished and hold great significance in elevating the level of scientific research we conduct. Below you will find key updates from the RESPOND study.

Since its inception, RESPOND has published 29 manuscripts, had 39 presentations at international conferences, and influenced guideline changes such as International AIDS Society (IAS) guidelines. In 2025 to date RESPOND has published 6 manuscripts. We would like to congratulate all authors, contributors and study participants: without the combined efforts of everyone involved in this collaboration this would not have been possible.

Sincerely,

The RESPOND Secretariat

Study Updates

Dataset 7 (DS7)

We have finished cleaning the latest Dataset 7 (DS7). DS7 includes data up to 31st December 2024. The large RESPOND data lake contains data from a total of 45,033 participants (contributing 350,000 person years of follow-up), of which 28,785 are under active follow-up.

Collaborating cohorts

To date, fourteen cohorts remain active in RESPOND. Three cohorts were inactivated for further follow-up in 2025 due to long-term data quality and completeness issues. The collaboration appreciates the ongoing cohort efforts to improve in this regard and will reengage in conversations on reactivation of participation when the required standards are met.

Dataset 8 (DS8)

Dataset 8 (DS8) opened for data submission on 1st September 2025. The deadline for submission is **1st December 2025**.

Deadlines

- Deadline for data submission: **1st December 2025**
- Deadline for resubmission: **1st January 2026**
- Deadline for the Event and CoDe forms submission in REDCap: **1st April 2026**

Reimbursement

While we are pleased to share that funding has been secured for RESPOND through 2026 and 2027, the funding is at a substantially lower level than in previous years, which means we are faced with the need to implement significant budget cuts across the study.

The RESPOND Scientific Steering Committee and Executive Committee have agreed on several necessary budget balancing steps which include pausing reimbursement of new enrolments for the next two datasets, to be reassessed in 2027. We warmly welcome the enrollment of new RESPOND participants who wish to contribute *in-kind data*. To ensure a smooth process, please kindly contact the RESPOND Secretariat (respond.rigshospitalet@regionh.dk) before submitting any new participants' data.

Additionally, the reimbursement for *follow-up forms will be reduced from €20 to €15*, effective from dataset 8, autumn 2025. Please note that the reimbursement for completed and validated clinical event and CoDe forms will remain at **€30**.

We truly appreciate your understanding and continued commitment to RESPOND. Please be assured that RESPOND management remains committed to seeking additional funding opportunities to help address these constraints wherever possible.

RESPOND scientific retreat in conjunction with EACS, October 2025, Paris

Thank you to those attending the RESPOND Scientific Retreat in October 2025 in Paris! Many exciting ongoing and upcoming scientific projects were discussed, and we are excited to share future updates on these projects with you as they develop.

Other updates:

- Since 2025 the RESPOND Annual Retreat is moved to EACS/Glasgow HIV instead of IWHOD.

Upcoming meetings

- RESPOND Scientific Steering Committee VC on **9th December 2025 at 21:00 CET**
- RESPOND Executive Committee VC on **16th December 2025 at 21:00 CET**

Scientific presentations and publications in 2025

Presentations 2025

Conference on Retrovirus and Opportunistic Infections (CROI 2025), San Francisco, California, USA, 9-12 March 2025

- Poster presentation:
Cancer Incidence in Women With HIV in Europe and Australia: A Combined D:A:D and Respond Analysis presented by Win Min Han on behalf of the RESPOND and D:A:D study groups. [Poster](#)
- Poster presentation:
Determinants of Steatotic Liver Disease Among People With HIV in Europe and Australia presented by Carlotta Riebensahm on behalf of the RESPOND study group. [Poster](#)

IWHOD, Toledo, Spain, 27th to 29th March 2025

- Poster presentation:
CD4 Cell Count Trends After Common Cancers in People With HIV presented by Alisa Timiryasova on behalf of the RESPOND Scientific Group. [Poster](#)

Nordic HIV and Virology Conference, Stockholm, Sweden. 24-25 September 2025

- Poster presentation:
CD4 Cell Count Trends After Common Cancers in People With HIV presented by Alisa Timiryasova on behalf of the RESPOND Scientific Group. [Poster](#)

Upcoming presentations in 2026

Conference on Retrovirus and Opportunistic Infections (CROI 2026), Denver, Colorado, USA, 22-25 February 2026

- Accepted for poster presentation:
Evaluating the Impact of Integrase Inhibitors (INSTIs) on Cardiovascular Disease (CVD) will be presented by Bastian Neesgaard on behalf of the RESPOND Scientific Group.

Publications 2025

1. **Viremia does not independently predict cardiovascular disease in people with HIV: a RESPOND cohort study.** Elvstam O, Ryom L, Neesgaard B, Tau L, Günthard H F, Zangerle R, Vehreschild J J, Wit F, Sönnernborg A, Kovari H, Abutidze A, Petoumenos K, Jaschinski J, Hosein S, Bogner J, Grabmeier-Pfistershammer K, Garges H, Rooney J, Young L, Law M, Kirk O for the RESPOND Study Group.
Open Forum Infectious Diseases 2025. Jan 13;12(2):ofaf016. [Abstract](#)
2. **A simple tool to evaluate the effectiveness of HIV care for settings with gaps in data availability (ESTIHIV).** Raben D, Jakobsen M L, Trajanovska J, Kowalska J, Vassilenko A, Dragas S, Harxhi A, Dragovic G J, Jaschinski N, Neesgaard B, Hjorth-Larsen K, Garges H, Gallant J, Lundgren J D, Philips A, Cambiano V, Yazdanpanah Y and Mocroft A.
PLOS One 2025. Jan 29;20(1):e0316794. [Abstract](#)
3. **Incident tuberculosis in people with HIV across Europe from 2012-2022: incidence rates, risk factors, and regional differences in a multicentre cohort study.** Kraef C, Roen A, Podlekareva D, Bakowska E, Nemeth J, Knappik M, Payen M-C, Wit F, Mussini C, d'Arminio Monforte A, Castagna A, Chkhartishvili N, Neesgaard B, Jaschinski N, Volny Anne A, Borodulina E, Ballief M, Wallner E, Israelski D, Garges H, Mocroft A, Kirk O and the RESPOND Study Group.
European Respiratory Journal 2025. Feb 20:2401904. [Abstract](#)
4. **Risk of cancer in people with HIV experiencing varying degrees of immune recovery with sustained virological suppression on antiretroviral treatment for more than 2 years: an international, multicentre, observational cohort.** Han WM, Ryom L, Sabin C, Greenberg L, Cavassini M, Egle A, Duvivier C, Wit F, Mussini C, d'Arminio Monforte A, Castagna A, Miro JM, van der Valk M, Bonnet F, Pradier C, Skocic M, Matulionyte R, Stöckle M, Jaschinski N, Timiryasova A, Tallada J, Rogatto FP, Vannappagari V, Young LA, Lundgren JD,

Petoumenos K, Hoy JF.

Clinical Infectious Diseases 2025. May 15:ciaf248. [Abstract](#)

5. **Mortality using raltegravir versus other integrase strand-transfer inhibitors in people with HIV in Europe and Australia: a prospective multicentre study** Tusch E, Ryom L, Hoffmann C, Degen O, Zangerle R, Günthard HF, Wit F, Mussini C, Castagna A, Martin C, Giacomelli A, Vehreschild JJ, Begovac J, Vannappagari V, Rooney J, Mendes SDS, Tallada J, Kowalska J, Wallner E, Kusejko K, Jaschinski N, Lundgren J, Peters L, Reekie J
eClinicalMedicine 2025 Sep 20:89:103521 [Abstract](#)
6. **Use of Preventive Measures for Cardiovascular Disease in People with HIV** N. Jaschinski, B. Neesgaard, F. Wit, M. Van der Valk, J. Kowalska, A.L. Ridolfo, H. F. Günthard, M. Stöckle, E. Wallner, P. Nowak, A. Castagna, A. d'Arminio Monforte, K. Petoumenos, J. Hoy, S. Hosein, J. Lundgren, H. Garges, F. Rogatto, L. Young, L. Peters, A. Mocroft, and L. Ryom on behalf of the RESPOND Study Group*
Open Forum Infectious Diseases (in press)

For a full overview of all RESPOND presentations and publications, please see the [RESPOND website](#), and to stay up to date with ongoing and upcoming research activities, follow RESPOND on [X](#).

Thank you once again for your ongoing support and contributions to the study. If you have any questions or require further clarification, please don't hesitate to reach out.

We wish all participants and collaborators in the RESPOND study a wonderful winter holiday season and look forward to continuing our great collaboration in the new year.

Sincerely,

The RESPOND Secretariat



Contact

Please always feel free to contact the RESPOND Secretariat at respond.rigshospitalet@regionh.dk.

No question is too small or too big, we are happy to assist in all matters!

RESPOND Secretariat

Rigshospitalet

CHIP, Section 2100

Blegdamsvej 9 · Copenhagen 2100 · Denmark